Oncology & Cancer

Researchers discover why some colon cancers resist treatment

Researchers at The Tisch Cancer Institute at Mount Sinai have uncovered a major reason why some colorectal cancers (CRC) resist treatment. Their study, published this week in Nature Genetics, reveals that cancer cells can ...

Oncology & Cancer

Cancer drugs cause chronic peripheral nerve pain in 40% of patients

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around four in every 10 patients treated with these drugs, suggests a pooled data analysis of the available evidence, published ...

page 1 from 4

A fundamental philosophy of combination cancer therapy is that different drugs work through different cytotoxic mechanisms. Because they have different dose-limiting adverse effects, they can be given together at full doses in chemotherapy regimens.

The term "induction regimen" refers to a chemotherapy regimen which is used for the initial treatment of a disease.

Chemotherapy regimens are often identified by acronyms, identifying the agents used in combination. However, the letters used are not consistent across regimens, and in some cases (for example, "BEACOPP") the same letter combination is used to represent two different treatments: there is not a naming standard for chemotherapy regimens. This page merely lists commonly used conventions.

This text uses material from Wikipedia licensed under CC BY-SA